Scientists at Stanford University are currently preparing the first human test of a cancer “vaccine,” a treatment that eliminated up to 97 percent of tumors during trials with mice. Appropriately 35 people with lymphoma will begin the trials before the end of 2018. Not technically a vaccine, the new cancer treatment is a kind of immunotherapy that involves an injection of two agents directly into a tumor. These agents stimulate the production of T cells, which then fight the cancer. As promising as the treatment may be, it is still a long way from being ready for and available to the public.
In mice trials, the cancer vaccine eliminated tumors in 87 out of 90 mice, all of which suffered from various kinds of cancer, including lymphoma, breast cancer, and colon cancer. The vaccine proved effective even in instances when cancer had spread to other parts of the body. As exciting as this development may be, it is too early to properly evaluate. “We’ve been able to cure a lot of cancers in mice for a long time,” Dr. Alice Police, the regional director of breast surgery at Northwell Health Cancer Institute, told Live Science.
Police also pointed out that since the human test only includes lymphoma patients, it will take more time and research before it can be determined whether or not the cancer vaccine is effective against other kinds of cancer in humans. Nonetheless, the cancer vaccine is a promising alternative to existing immunotherapies. “When we use these two agents together, we see the elimination of tumors all over the body,” said Stanford oncology professor Ronald Levy, MD in a statement. “This approach bypasses the need to identify tumor-specific immune targets and doesn’t require wholesale activation of the immune system or customization of a patient’s immune cells.”
Via Live Science